2026年1月6日融资动态
Financings for Jan. 6, 2026
生命科学资讯
生物技术与制药领域的最新动态
2026年1月6日人事任命与晋升
Appointments and advancements for Jan. 6, 2026
2026年1月6日其他值得关注的新闻
Other news to note for Jan. 6, 2026
2026年1月6日监管行动
Regulatory actions for Jan. 6, 2026
Illumina股价为何在推进Grail剥离计划后上涨6.5%？未来走向如何——雅虎财经解读
Why Illumina (ILMN) Is Up 6.5% After Advancing Grail Divestiture Plan And What's Next - Yahoo Finance
Illumina股价上涨6.5%：推进Grail剥离计划后的市场反应与未来展望 - 雅虎财经英国版
Why Illumina (ILMN) Is Up 6.5% After Advancing Grail Divestiture Plan And What's Next - Yahoo Finance UK
赛默飞世尔科技（NYSE:TMO）创下52周新高——现在该买入吗？——MarketBeat
Thermo Fisher Scientific (NYSE:TMO) Sets New 52-Week High - Should You Buy? - MarketBeat
Evercore ISI集团上调安捷伦科技(A)评级 - 纳斯达克
Evercore ISI Group Upgrades Agilent Technologies (A) - Nasdaq
视觉皮层MT区对多种运动速度的神经编码
Neural coding of multiple motion speeds in visual cortical area MT
猕猴V1区上下文调节对层间信号流的依赖性
Dependence of contextual modulation in macaque V1 on interlaminar signal flow
解码HIV诱导的CPSF6斑点的生物发生及其与核斑点的融合
Decoding the biogenesis of HIV-induced CPSF6 puncta and their fusion with nuclear speckles
水稻条纹病毒利用灰飞虱唾液碳酸酐酶通过直接分子相互作用促进植物感染
Rice stripe virus utilizes a Laodelphax striatellus salivary carbonic anhydrase to facilitate plant infection by direct molecular interaction
流感病毒准种内遗传序列异质性通过单分子测序揭示
Heterogeneity of genetic sequence within quasi-species of influenza virus revealed by single-molecule sequencing
上诉法院裁定反对NIH间接成本削减计划。
Appeals court rules against NIH’s indirect cost cut plan
安捷伦科技公司的真相：这只低调的实验室股票或成你的下一张王牌——特别报道
The Truth About Agilent Technologies Inc: Quiet Lab Stock That Might Be Your Next Power Play - AD HOC NEWS
花旗维持对安捷伦科技(A.US)的买入评级 - 富途牛牛
Citi Maintains Agilent Technologies(A.US) With Buy Rating - 富途牛牛
赛默飞世尔科技股价创52周新高，达610.97美元
Thermo Fisher Scientific stock reaches 52-week high at $610.97 By Investing.com - Investing.com Nigeria
驾驭人工智能浪潮：制药业如何在企业资源规划中运用智能代理
Surfing the AI wave: How pharma can harness agents in ERP
赛默飞世尔科技股价创52周新高，达610.97美元 - Investing.com
Thermo Fisher Scientific stock reaches 52-week high at $610.97 - Investing.com
FDA在拒绝信中提出新问题，涉及赛诺菲多发性硬化症药物。
FDA raises new questions with Sanofi's MS drug in release of rejection letter